Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.97 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gyki-52466 SCHEMBL29357520 | 1.00 | GRIA2 (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| Gyki-52466 SCHEMBL29651319 | 0.99 | LMNA (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| Gyki-52466 SCHEMBL25227675 | 0.99 | LMNA (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| Gyki-52466 SCHEMBL249675 | 0.99 | LMNA (1.00) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10887479 | 0.86 | GRIA2 (0.76) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7492463 | 0.82 | MAPT (0.69) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL350464 | 0.81 | GRIA2 (0.68) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7164964 | 0.81 | GRIA2 (0.68) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8795316 | 0.81 | GRIA2 (0.67) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5048632 | 0.81 | GRIA2 (0.67) | GRIA2MEN1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170035754-A1 | METHODS AND COMPOUNDS FOR PREVENTING OSTEOARTHRITIS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2017-02-09 | — | — | US | claimed |
| EP-2255798-B1 | FTY720 for use in the treatment of optic neuritis | NOVARTIS AG (CH) | 2014-12-24 | — | — | EP | claimed |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | NOVARTIS AG (CH) | 2014-06-12 | — | — | US | claimed |
| EP-2213285-B1 | Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases | NOVARTIS AG (CH) | 2013-11-06 | — | — | EP | claimed |
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | claimed |
| US-7750024-B2 | Remedy for glioblastoma | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | claimed |
| US-7192931-B2 | Treatment of demyelinating diseases | NEUREN PHARMACEUTICALS LTD. (NZ) | 2007-03-20 | — | — | US | claimed |
| US-20050182047-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2005-08-18 | — | — | US | claimed |
| US-20040204347-A1 | Treatment of demyelinating disorders | EISAI CO., LTD. (JP) | 2004-10-14 | — | — | US | claimed |
| US-6797692-B1 | Use of glutamate antagonists for the treatment of cancer | IKONOMIDOU HRISSANTHI (DE) | 2004-09-28 | — | — | US | claimed |
| EP-1359933-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | Neuronz Limited (NZ) | 2003-11-12 | — | — | EP | claimed |
| JP-2002539162-A | — | — | 2002-11-19 | — | — | JP | claimed |
| WO-2002030447-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| WO-2002030448-A2 | TREATMENT OF DEMYELINATING DISEASES BY ADMINISTERING GPE | NEURONZ LTD. (NZ) | 2002-04-18 | — | — | WO | claimed |
| EP-1161238-A1 | AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST | Aventis Pharma S.A. (FR) | 2001-12-12 | — | — | EP | claimed |
| EP-1124553-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | Ikonomidou, Hrissanthi (DE) | 2001-08-22 | — | — | EP | claimed |
| WO-2000054772-A1 | AMYOTROPIC LATERAL SCLEROSIS TREATMENT WITH A COMBINATION OF RILUZOLE AND AN AMPA RECEPTOR ANTAGONIST | AVENTIS PHARMA S.A. (FR) | 2000-09-21 | — | — | WO | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-2000024395-A1 | NEW USE OF GLUTAMATE ANTAGONISTS FOR THE TREATMENT OF CANCER | IKONOMIDOU HRISSANTHI (DE) | 2000-05-04 | — | — | WO | claimed |
| US-4614740-A | NERVOUS SYSTEM DISORDERS | EGIS GYOGYSZERGYAR (HU) | 1986-09-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204347-A1 | Treatment of demyelinating disorders | GRIK4, GRIK5, PMP22 | GRIA2 21/4885MEN1 3154/4885CYP1A2 4690/4885 |
| US-20140162964-A1 | USE IN BRAIN DEGENERATIVE DISEASES | S1PR1, S1PR2, S1PR3 | GRIA2 201/4885MEN1 3244/4885CYP1A2 4760/4885 |
| US-20050182047-A1 | Treatment of demyelinating disorders | GRIK4, PMP22, GRIK5 | GRIA2 21/4885MEN1 3073/4885CYP1A2 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.